Is CD37-targeted therapy a viable alternative in the treatment of diffuse large B-cell lymphoma? Interviews with two key opinion leaders

Grzegorz S. Nowakowski¹, Wojciech Jurczak²

EMJ. 2021;6[1]:33-39

¹Mayo Clinic, Rochester, Minnesota, USA
²Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland